<DOC>
	<DOC>NCT01976338</DOC>
	<brief_summary>To provide efficacy and safety data on intravitreal injections of ranibizumab 0.5 mg in patients with visual impairment due to macular edema secondary to BRVO</brief_summary>
	<brief_title>Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO)</brief_title>
	<detailed_description />
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>â€¢ Patients with visual impairment secondary to branch retinal vein occlusion (BRVO) with a BCVA between 19 and 73 letters in one eye and at least 35 letters in the other eye. Pregnant or nursing women or women of child bearing potential without using an effective contraception Stroke or myocard infarction within 3 months prior to study History of malignancy within the past 5 years Uncontrolled hypertension Active infection or inflammation in any eye monocular patients use of corticosteroids for at least 30 days in the last 6 months treatment with antiangiogenic drugs in any eye within last 3 months laser photocoagulation within the last few months Other protocol defined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>BRVO, macular edema, vision impairment, retinal vein occlusion, ranibizumab</keyword>
</DOC>